Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE

Approved

STANDARD

AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE

Glaxosmithkline Biologicals🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 12, 2023
Approval ID: e88a9700de9ce080
Company: Glaxosmithkline Biologicals
Type: Standard

Approval Details

Approval Id: e88a9700de9ce080
Drug Cima Aemps Name: AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE
Register Number: 1231740001
Holder Company Name: Glaxosmithkline Biologicals
Marketing Company Name: Glaxosmithkline S.A.
Holder Company Detail Path: /organization/glaxosmithkline-biologicals
Marketing Company Detail Path: /organization/glaxosmithkline-sa
Authorization Date: 2023-06-12
Dosage Form: POLVO Y SUSPENSIÓN PARA SUSPENSIÓN INYECTABLE
Dose: 0,5 ML
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Glaxosmithkline Biologicals
Company Detail Path: /organization/glaxosmithkline-biologicals

Company Information

Pharmaceutical Company Name: GLAXOSMITHKLINE BIOLOGICALS
Country Name: France
City Name: st amand les eaux,hauts de france,country_fr
Address: 637 RUE DES AULNOIS

Active Ingredients

VACUNA (RSVPREF) DE SUBUNIDAD F ESTABILIZADA EN PREFUSION FRENTE AL VIRUS RESPIRATORIO SINCITIAL.

120 µg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 12, 2023

Approval ID

e88a9700de9ce080

Type

Standard

Back to CIMA-AEMPS Approvals